ADNI 3
ADNI3 began in 2016, with an expanded goal of determining the relationships between the clinical, cognitive, imaging, genetic, and biochemical biomarker characteristics across the entire spectrum of AD. ADNI3 adds brain scans that detect tau protein tangles (tau PET), a key indicator of the disease. This phase also continues the discovery, optimization, standardization, and validation of clinical trial measures and biomarkers used in AD research.
ADNI3 includes scientists at 59 research centers in the United States and Canada and will add hundreds of new MCI subjects, mild AD subjects, and elderly controls.
Further Reading